CRBUCaribou Biosciences, Inc.同业对比
Caribou Biosciences, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRBU本股 | $48M#8 | — | 0.5x#3 | 4.3x#2 | 11.7%#2 | 0.7%#4 | -1329.4%#2 | -151.0%#8 | — | — | -79.5%#14 | — |
| CRDF | $67M#1 | — | 2.5x#10 | 113.5x#4 | -13.2%#3 | -0.9%#5 | -8256.3%#4 | -0.2%#1 | — | — | -61.2%#11 | — |
| CGTX | $65M#2 | — | 2.0x#9 | — | — | 30.9%#2 | — | -71.1%#6 | — | — | -56.5%#8 | — |
| GRMLW | $57M#3 | — | 1.0x#5 | — | — | -71.6%#13 | — | -18.2%#3 | -14.6%#1 | — | 105.7%#2 | — |
| INKT | $55M#4 | — | — | — | — | -15.9%#8 | — | — | — | — | -23.4%#5 | — |
| BKHAU | $54M#5 | — | — | — | — | -30.6%#10 | — | — | — | — | 136.5%#1 | 94.1%#1 |
| ELOX | $53M#6 | 3.7x#2 | 1.1x#6 | — | -100.0%#5 | -90.7%#14 | — | -12.9%#2 | — | — | — | — |
| KLRS | $48M#7 | — | 0.8x#4 | 292.9x#5 | — | 37.2%#1 | -27970.9%#6 | -75.3%#7 | — | — | -58.8%#9 | — |
| TIL | $48M#9 | — | 0.4x#2 | — | -100.0%#5 | 3.7%#3 | — | -66.5%#5 | — | — | -55.6%#7 | — |
| IMA | $47M#10 | — | 0.3x#1 | 58.2x#3 | -77.1%#4 | -24.0%#9 | -6056.4%#3 | -31.9%#4 | — | — | -50.8%#6 | — |
| LONA | $45M#11 | — | 1.3x#7 | — | — | -9.3%#6 | — | -315.5%#11 | — | — | 17.0%#3 | — |
| EXOZ | $41M#12 | — | 11.3x#11 | 588.1x#6 | — | -56.3%#12 | -13867.0%#5 | -250.6%#10 | — | — | -60.3%#10 | — |
| TVGN | $41M#13 | — | — | — | — | -91.4%#15 | — | — | — | — | -78.5%#13 | — |
| PTHS | $39M#14 | — | — | 2.3x#1 | — | -444.6%#16 | -193.1%#1 | — | — | — | -70.3%#12 | — |
| INMB | $37M#15 | — | 1.8x#8 | 743.8x#7 | 257.1%#1 | -9.5%#7 | -94766.0%#7 | -225.9%#9 | -607.3%#2 | — | -22.1%#4 | — |
| IRLA | $32M#16 | 0.3x#1 | — | — | — | -47.8%#11 | — | — | — | — | -90.1%#15 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议